• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFR14A filed by eXoZymes Inc.

    6/23/25 5:29:41 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXOZ alert in real time by email
    DEFR14A 1 ny20050076x2_defr14a.htm DEFR14A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Amendment No. 1 to
    SCHEDULE 14A
    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
    SECURITIES EXCHANGE ACT OF 1934
    Filed by the Registrant ☒
    Filed by a Party other than the Registrant  ☐
    Check the appropriate box:
     ☐
    Preliminary Proxy Statement
     ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☒
    Definitive Proxy Statement
     ☐
    Definitive Additional Materials
     ☐
    Soliciting Material Pursuant to §240.14a-11(c) or §240.14a-2
    EXOZYMES INC.
    (Exact name of registrant as specified in its charter)
    Payment of Filing Fee (Check the appropriate box):
    ☒
    No fee required.
     ☐
    Fee paid previously with preliminary materials.
     ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

    EXPLANATION OF FILING
    This filing is being made to correct the proxy card that was filed on June 20, 2025 by ExoZymes Inc. The change is to correct the voting for director nominees.
    The proposal number 1 originally did not provide for the ability of a shareholder to withhold for all or for one or more of the director nominees. The card has been adjusted to provide for the ability of the shareholder to select either a vote “For All,” “Withhold All” or “For All Except” and an explanation as to how to withhold authority for a specific director nominee for those shareholders selecting to vote “For All Except.”
    As the proxy materials have not yet been distributed as of the date of this filing, shareholders will only be receiving the corrected proxy card; therefore there is not being provided to shareholders differently colored or otherwise separately distinguishable proxy cards.


     


     
    Get the next $EXOZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXOZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EXOZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bringing clarity and precision to the cell-free space by introducing exozymes

    Scientific definition of exozymes featured as cover story in GEN Biotechnology, freely available as an Open Access paper The author team introduces the terms ‘exozymes' to bring clarity to the rapidly evolving field of cell-free biomanufacturing—a biomanufacturing method to produce chemicals without relying on living cells like bacteria or yeast The paper features co-authors from multiple institutions such as The National Renewable Laboratory (NREL), UCLA, Caltech, University of Colorado Boulder, Sepia Biosciences, as well as the venture studio, Ferment  The authors intend the terms to be freely available for use by the broader scientific community, and no trademarks have been filed Mon

    4/21/25 4:10:00 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant

    Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its latest initiative - BioClick - a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created. At the heart of BioClick is a focus on group transfer reactions, a class of biochemical reactions that allow enzym

    4/10/25 4:30:00 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

    Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus on developing commercial opportunities, spin-outs, joint-ventures, and licensing deals with future partners Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO). Perriman brings more than two decades of experience i

    4/2/25 4:10:00 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXOZ
    SEC Filings

    View All

    eXoZymes Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - EXOZYMES INC. (0002010788) (Filer)

    10/3/25 3:47:11 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by eXoZymes Inc.

    10-Q - EXOZYMES INC. (0002010788) (Filer)

    8/12/25 4:11:20 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    eXoZymes Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - EXOZYMES INC. (0002010788) (Filer)

    6/26/25 4:58:26 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXOZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Heltzen Michael bought $10,629 worth of shares (1,040 units at $10.22), increasing direct ownership by 11% to 10,629 units (SEC Form 4)

    4 - EXOZYMES INC. (0002010788) (Issuer)

    7/2/25 5:49:40 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXOZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Heltzen Michael bought $10,629 worth of shares (1,040 units at $10.22), increasing direct ownership by 11% to 10,629 units (SEC Form 4)

    4 - EXOZYMES INC. (0002010788) (Issuer)

    7/2/25 5:49:40 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Executive Officer Heltzen Michael

    4 - EXOZYMES INC. (0002010788) (Issuer)

    6/20/25 12:31:31 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vice President, Research Korman Tyler Paz was granted 2,990 shares, increasing direct ownership by 0.41% to 725,291 units (SEC Form 4)

    4 - EXOZYMES INC. (0002010788) (Issuer)

    6/17/25 5:22:49 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EXOZ
    Financials

    Live finance-specific insights

    View All

    eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

    Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus on developing commercial opportunities, spin-outs, joint-ventures, and licensing deals with future partners Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO). Perriman brings more than two decades of experience i

    4/2/25 4:10:00 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025

    Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday, April 2, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2024. A press release detailing these results will be issued prior to the call. Michael Heltzen, CEO of eXoZymes will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. Investors can pre-regi

    3/26/25 5:00:00 PM ET
    $EXOZ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care